相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Momelotinib is a highly potent inhibitor of FLT3-mutant AML
Mohammad Azhar et al.
BLOOD ADVANCES (2022)
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
Ruiqi Zhu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Christoph Rummelt et al.
LEUKEMIA (2021)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
LaQuita M. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
Defining a new nomenclature for the structures of active and inactive kinases
Vivek Modi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations
Ruchi Pandey et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics
Tristan Knight et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
Christine M. McMahon et al.
BLOOD ADVANCES (2019)
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
Pamela J. Sung et al.
BLOOD ADVANCES (2019)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia
Meenu Kesarwani et al.
NATURE MEDICINE (2017)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Fangli Chen et al.
ONCOTARGET (2016)
Targeting substrate- site in Jak2 kinase prevents emergence of genetic resistance
Meenu Kesarwani et al.
SCIENTIFIC REPORTS (2015)
Targeting Conformational Plasticity of Protein Kinases
Michael Tong et al.
ACS CHEMICAL BIOLOGY (2015)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Fast Docking Using the CHARMM Force Field with EADock DSS
Aurelien Grosdidier et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2011)
CHARMM: The Biomolecular Simulation Program
B. R. Brooks et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
FACTS:: Fast analytical continuum treatment of solvation
Urs Haberthuer et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2008)
Self-renewal of embryonic stem cells by a small molecule
Shuibing Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mohammad Azam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
分享论文
